× Digital News Videos Health & Science Lifestyle Opinion Education Columnists Moi Cabinets Arts & Culture Ureport Fact Check The Standard Insider Kenya @ 50 Podcasts E-Paper Lifestyle & Entertainment Nairobian Entertainment Eve Woman Travelog TV Stations KTN Home KTN News BTV KTN Farmers TV Radio Stations Radio Maisha Spice FM Vybez Radio Enterprise VAS E-Learning Digger Classified Games Crosswords Sudoku The Standard Group Corporate Contact Us Rate Card Vacancies DCX O.M Portal Corporate Email RMS

Drug that shortens recovery time for Covid-19 patients to be availed in Kenya

By Macharia Kamau | July 11th 2020 at 00:00:00 GMT +0300

Indian firm Cipla will distribute remdesivir in Kenya, an antiviral drug that could be critical in the management of Covid-19.

Cipla entered into an agreement with America’s Gilead Sciences, which owns the patent for the drug, granting it a licence to manufacture and distribute the drug in 127 countries, including Kenya.

Remdesivir received the Emergency Use Authorisation for treating Covid-19 by the US Food and Drug Administration on May 1. "Cipla will make remdesivir available in Kenya at a significantly reduced price,” said Martin Sweeney, Commercial head of Cipla in Sub-Saharan Africa.

Covid 19 Time Series


remdesivir Cipla Covid-19
Share this story

More stories